SANES

9.46

-0.05%↓

BBVA

18.845

-1.1%↓

ALV

366.8

-0.33%↓

MUV2

531.4

-0.71%↓

INGA

22.67

-0.15%↓

SANES

9.46

-0.05%↓

BBVA

18.845

-1.1%↓

ALV

366.8

-0.33%↓

MUV2

531.4

-0.71%↓

INGA

22.67

-0.15%↓

SANES

9.46

-0.05%↓

BBVA

18.845

-1.1%↓

ALV

366.8

-0.33%↓

MUV2

531.4

-0.71%↓

INGA

22.67

-0.15%↓

SANES

9.46

-0.05%↓

BBVA

18.845

-1.1%↓

ALV

366.8

-0.33%↓

MUV2

531.4

-0.71%↓

INGA

22.67

-0.15%↓

SANES

9.46

-0.05%↓

BBVA

18.845

-1.1%↓

ALV

366.8

-0.33%↓

MUV2

531.4

-0.71%↓

INGA

22.67

-0.15%↓

Search

Bayer AG

Suletud

SektorRahandus

33.365 -0.42

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

33.32

Max

33.43

Põhinäitajad

By Trading Economics

Sissetulek

-773M

-963M

Müük

-1.1B

9.7B

Aktsiakasum

1.23

Dividenditootlus

0.36

Kasumimarginaal

-9.969

Töötajad

88,502

EBITDA

-3.4B

236M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-6.13% downside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.36%

3.86%

Turustatistika

By TradingEconomics

Turukapital

3.5B

30B

Eelmine avamishind

33.79

Eelmine sulgemishind

33.365

Uudiste sentiment

By Acuity

47%

53%

172 / 528 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Bayer AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. nov 2025, 11:12 UTC

Suurimad hinnamuutused turgudel

Bayer Shares Jump After Drug Candidate Shows Stroke Prevention Potential -- Update

12. nov 2025, 07:32 UTC

Tulu

Bayer Posts Net Loss on Litigation Hit

6. aug 2025, 06:18 UTC

Tulu

Bayer Loss Widens on Litigation Charges

24. nov 2025, 09:50 UTC

Kuumad aktsiad
Omandamised, ülevõtmised, äriostud

Stocks to Watch Monday: Alibaba, Tesla, Alphabet, Bayer -- WSJ

12. nov 2025, 11:15 UTC

Market Talk
Tulu

Bayer's Crop Science Unit Drives Strong Results -- Market Talk

12. nov 2025, 06:33 UTC

Tulu

Bayer Affirms Objective to Significantly Contain Litigation Risk by End of 2026

12. nov 2025, 06:31 UTC

Tulu

Analysts Had Seen Bayer 3Q Net Loss at EUR413M

12. nov 2025, 06:31 UTC

Tulu

Bayer 3Q Net Loss EUR963M

12. nov 2025, 06:30 UTC

Tulu

Analysts Had Seen Bayer 3Q EBITDA Before Special Items at EUR1.27B

12. nov 2025, 06:30 UTC

Tulu

Bayer 3Q EBITDA Before Special Items EUR1.51B

12. nov 2025, 06:30 UTC

Tulu

Analysts Had Seen Bayer 3Q Sales at EUR9.69B

12. nov 2025, 06:30 UTC

Tulu

Bayer 3Q Sales EUR9.66B

12. nov 2025, 06:30 UTC

Tulu

Bayer Backs 2025 View

6. aug 2025, 15:01 UTC

Market Talk
Tulu

Bayer Expects Bumper U.S. Crop -- Market Talk

6. aug 2025, 14:52 UTC

Market Talk

Bayer says Litigation Situation With Roundup 'Unsustainable' -- Market Talk

6. aug 2025, 09:05 UTC

Market Talk

Bayer Expects Weedkiller Dicamba Back on U.S. Market in 2026 -- Market Talk

6. aug 2025, 07:27 UTC

Market Talk
Tulu

Bayer's Results Deliver Few Surprises -- Market Talk

6. aug 2025, 05:43 UTC

Tulu

Bayer: Crop Science Division Now in a Position to Streamline Production and Operations

6. aug 2025, 05:43 UTC

Tulu

Bayer: Making Headway on Plan to Improve Profitability in Agricultural Business

6. aug 2025, 05:42 UTC

Tulu

Bayer Affirms Objective to Significantly Contain Litigation Risk by End of 2026

6. aug 2025, 05:41 UTC

Tulu

Bayer Expects Significant Currency Fluctuations With Headwinds on Sales and Profits, Favorable Effects on Debt

6. aug 2025, 05:41 UTC

Tulu

Bayer: 2H Will Be Marked by Progress on Strategic Priorities, Launches, Geopolitical and Currency Crosswinds

6. aug 2025, 05:33 UTC

Tulu

Bayer 2Q Net Loss EUR199M

6. aug 2025, 05:32 UTC

Tulu

Bayer Had Pre-Announced 2Q Ebitda Before Special Items at EUR2.1B

6. aug 2025, 05:32 UTC

Tulu

Bayer 2Q Ebitda Before Special Items EUR2.11B

6. aug 2025, 05:32 UTC

Tulu

Bayer Had Pre-Announced 2Q Sales at EUR10.7B

6. aug 2025, 05:32 UTC

Tulu

Bayer 2Q Sales EUR10.74B

30. juuni 2025, 15:09 UTC

Market Talk

Supreme Court Asks for Government's View on Bayer's Roundup Case -- Market Talk

5. juuni 2025, 08:29 UTC

Market Talk

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30. mai 2025, 13:47 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Bayer AG Prognoos

Hinnasiht

By TipRanks

-6.13% langus

12 kuu keskmine prognoos

Keskmine 31.26 EUR  -6.13%

Kõrge 40 EUR

Madal 23 EUR

Põhineb 12 Wall Streeti analüütiku instrumendi Bayer AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

5

Osta

7

Hoia

0

Müü

Tehniline skoor

By Trading Central

22.99 / 23.88Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

172 / 528 Pingereas Rahandus

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
help-icon Live chat